Rocket Pharmaceuticals (RCKT)
(Delayed Data from NSDQ)
$23.38 USD
+0.29 (1.26%)
Updated May 14, 2024 04:00 PM ET
After-Market: $23.39 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
RCKT 23.38 +0.29(1.26%)
Will RCKT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RCKT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RCKT
Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why
RCKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia
Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report?
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4
Other News for RCKT
Cantor picks 14 undervalued biotech stocks worth a second look
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Rocket announces data updates from its lentiviral portfolio
Analysts’ Top Healthcare Picks: Vir Biotechnology (VIR), Rocket Pharmaceuticals (RCKT)
Optimistic Outlook for Rocket Pharmaceuticals with Advancing Pipeline and Solid Financials